Chemical Component Summary | |
|---|---|
| Name | amlodipine |
| Synonyms | ~{O}3-ethyl ~{O}5-methyl (4~{S})-2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Identifiers | ~{O}3-ethyl ~{O}5-methyl (4~{S})-2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Formula | C20 H25 Cl N2 O5 |
| Molecular Weight | 408.876 |
| Type | NON-POLYMER |
| Isomeric SMILES | CCOC(=O)C1=C(NC(=C([C@@H]1c2ccccc2Cl)C(=O)OC)C)COCCN |
| InChI | InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1 |
| InChIKey | HTIQEAQVCYTUBX-KRWDZBQOSA-N |
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 53 |
| Chiral Atom Count | 1 |
| Bond Count | 54 |
| Aromatic Bond Count | 6 |
Drug Info: DrugBank
| DrugBank ID | DB09237? |
|---|---|
| Name | Levamlodipine |
| Groups |
|
| Description | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication.[L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however.[L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.[A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833] |
| Synonyms |
|
| Brand Names |
|
| Indication | Levamlodipine is indicated alone or in combination to treat hypertension in adults and children.[L10833] |
| Categories |
|
| ATC-Code | C08CA17 |
| CAS number | 103129-82-4 |
Drug Targets
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAAL... | unknown | antagonist |
| Voltage-dependent L-type calcium channel subunit alpha-1D | MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTV... | unknown | antagonist |
| Nitric oxide synthase, endothelial | MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAP... | unknown | agonist |
| Nitric oxide synthase, inducible | MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLS... | unknown | agonist |
| Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate |
| View More | |||
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL2111097 |
| PubChem | 9822750 |
| ChEMBL | CHEMBL2111097 |
| ChEBI | CHEBI:53796 |
| CCDC/CSD | XOZRUZ |
